Brady Statement on President’s Drug Pricing Rules

Webp 10edited

Brady Statement on President’s Drug Pricing Rules

The following press release was published by the U.S. Congress Committee on Ways and Means on Nov. 25, 2020. It is reproduced in full below.

WASHINGTON - The top Republican on the House Ways and Means Committee Kevin Brady (R-TX) released the following statement after the Trump Administration finalized new rules regarding prescription drug pricing:

“We need to reduce the cost of overpriced drugs. That’s why House Republicans are championing H.R. 19, a bill comprised of bipartisan solutions to lower the cost of medicines for seniors while accelerating new cures and fixing perverse incentives in the Medicare drug program. We need a long-term, legislative solution to achieve our goal, and I believe HR 19 would accomplish the goal without raising seniors’ premiums or importing foreign price controls that slow down the development of new medical cures."

Background:

* H.R. 19, the Lower Costs, More Cures Act, is the bipartisan path forward to crack down on overpriced drugs while encouraging more cures, exactly the prescription America needs during a global pandemic.

* House Democrats continued to put politics over patients, rather than pass meaningful legislation.

* Senate Democrats abandoned bipartisanship.

SUBCOMMITTEE: Health

Source: U.S. Congress Committee on Ways and Means

More News